Delivery Order SPE2DB22D1202-SPE2DB25FUPR2

Award Date 1/15/25
Potential Completion Date 1/16/25
Potential Value $3.1K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The U.S. Defense Logistics Agency (DLA) awarded a $3,854.64 firm-fixed-price delivery order to Amerisourcebergen Drug Corp's Corporate Office division, a major pharmaceutical supplier to the federal government. This order is for the drug Rexulti (0.25 mg tablet, 30s) and has a completion date of May 21, 2024. Amerisourcebergen holds a single-award Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued up to $999,999,999.00 through December 2025. This IDC serves as the...
This federal contract award was made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $4,220.15 firm fixed-price delivery order is for the supply of Rexulti 0.5 mg tablets. The contract, which does not have a set-aside designation, has an ultimate completion date of August 22, 2024. In addition to this specific delivery order, AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC)...
The U.S. Defense Logistics Agency (DLA) awarded a $15,280.64 firm-fixed-price delivery order contract to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the supply of REXULTI 2 MG TABLET 30S, a pharmaceutical product, with a performance period through March 27, 2025. This delivery order is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop Support Medical, which provides a comprehensive range of...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $5,025.24, is for the delivery of Rexulti 0.5 mg tablets. It is a firm fixed-price delivery order with an ultimate completion date of October 30, 2024. The contract is not designated as a set-aside. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop...
This is a federal delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $14,470.83 firm fixed-price contract is for the supply of the prescription drug Rexulti 2 mg tablets, with a period of performance through April 2025. This delivery order is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop Support Medical, which...
This federal contract award is for the delivery of pharmaceutical products, specifically the medication Rexulti 1 mg tablet, to the Defense Logistics Agency (DLA). The contract, valued at $4,866.53, was awarded to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., a major pharmaceutical distribution company. The contract is a Firm Fixed Price Delivery Order that runs until February 22, 2024. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $3,592.57 firm fixed-price contract is for the delivery of Rexulti 1 mg tablets, a psychiatric medication. The contract has an ultimate completion date of July 5, 2024 and was awarded on July 3, 2024. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $3,606.39 firm fixed-price delivery order is for the supply of 4,566,121,371 units of the prescription drug Rexulti 2 mg tablet. The contract has an ultimate completion date of October 17, 2024. This delivery order is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) between AmerisourceBergen and...
This federal contract award to AmerisourceBergen Drug Corp, a subsidiary of the global pharmaceutical distribution company AmerisourceBergen Corporation, is a delivery order valued at $11,081.84 for the supply of the pharmaceutical product Rexulti 2 mg tablets. The award was made by the Defense Logistics Agency (DLA), a defense agency of the U.S. Department of Defense, and has a period of performance through March 27, 2024. This delivery order is placed under a larger indefinite delivery...
This federal contract award is for the delivery of Rexulti 1 mg tablets to the Defense Logistics Agency (DLA) Troop Support Medical. The contract has a ceiling value of $2,323.36 and a completion date of November 7, 2023. The prime contractor is Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., a major pharmaceutical distribution company. This contract is not designated as a set-aside. Amerisourcebergen Drug Corp holds a significant $999,999,999 Indefinite Delivery Contract (IDC)...
  • SPE2DB22D1202
    Indefinite Delivery Contract
  • SPE2DB22D1202-SPE2DB25FUPR2
    Delivery Order

The U.S. Defense Logistics Agency (DLA) awarded a $3,057.56 Firm Fixed Price delivery order contract to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of 4 mg Rexulti tablets. The contract has an ultimate completion date of January 16, 2025 and does not have a set-aside designation, indicating open competition.

AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The company also maintains a separate $750,000 IDC with the Department of Justice Federal Bureau of Investigation for similar medical products and prescription drugs.

Generated 4/21/25, 3:46 AM